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Besides locomotion, organ protection, and
calcium–phosphorus homeostasis, the three classical
functions of the skeleton, bone remodeling affects energy
metabolism through uncarboxylated osteocalcin, a recently
discovered hormone secreted by osteoblasts. This review
traces how energy metabolism affects osteoblasts through
the central control of bone mass involving leptin,
serotoninergic neurons, the hypothalamus, and the
sympathetic nervous system. Next, the role of osteocalcin
(insulin secretion, insulin sensitivity, and pancreas b-cell
proliferation) in the regulation of energy metabolism is
described. Then, the connections between insulin signaling
on osteoblasts and the release of uncarboxylated osteocalcin
during osteoclast bone resorption through osteoprotegerin
are reported. Finally, the understanding of this new bone
endocrinology will provide some insights into bone, kidney,
and energy metabolism in patients with chronic kidney
disease.
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The three classical functions of bone are locomotion, organ
protection such as the skull, and calcium–phosphorus
homeostasis. Locomotion has been critical for survival
throughout evolution. Indeed, maintaining an excellent bone
quality with good biomechanical properties is essential for
locomotion and fracture prevention. To achieve this goal,
bone tissue is constantly renewing itself through a physio-
logical process called ‘bone remodeling’, which repairs
microdamage and participates in fracture healing. Bone
remodeling involves specialized cells, starting with osteo-
clasts, which resorb preexisting bone. The osteoclasts then
leave the lacunae, and osteoblasts deposit bone matrix that is
secondarily mineralized to ﬁll the lacunae. In healthy adults,
bone remodeling is well balanced and can be seen as a true
homeostatic function. With aging, major physiological
functions including bone maintenance are altered. Osteo-
porosis, a major age-related disease, is characterized by
unbalanced bone remodeling, low bone mass, and altered
bone architecture, leading to increased susceptibility to
fractures, reduced mobility, and altered quality of life. In
chronic kidney diseases (CKD), bone health is also a major
issue.
1,2 CKD-related mineral and bone disorder has been
deﬁned as the systemic disorder of mineral and bone
metabolism because of CKD manifested by one or more of
the following: (1) abnormalities of calcium, phosphorus,
parathyroid hormone, or vitamin D metabolism; (2)
abnormalities in bone turnover, mineralization, volume,
linear growth, or strength; (3) and vascular or other soft
tissue calciﬁcations.
1
Bone remodeling is an active process that requires a large
energy input. This led to the hypothesis of Karsenty et al.
3
that states that energy metabolism may regulate bone
remodeling. This hypothesis was supported by the following
clinical facts: obesity protects from osteoporosis, low body
mass index increases fracture risk, and osteoporosis develops
in patients with hypogonadism (for example, postmenopau-
sal women, senior men, chemical castration). These observa-
tions suggest that appetite, reproduction, and bone might
be regulated by a common hormonal system. From an
endocrine viewpoint, if energy metabolism is able to regulate
bone remodeling, there must be a feedback loop, and bone
remodeling should affect energy metabolism. In the last few
years, our understanding of these processes has developed
greatly. This article will trace the course of development of
our understanding of this new bone endocrinology.
review http://www.kidney-international.org
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Association of leptin with bone mass
Leptin was the ﬁrst focus of research into the link between
energy metabolism and bone mass for several reasons:
(1) leptin is an adipocyte hormone that regulates appetite
(through inducing satiety and increasing energy expenditure)
and reproduction through its receptor expressed in the
hypothalamus and brainstem;
4,5 (2) leptin and bone
remodeling emerged at the same time in evolution;
6 and
(3) leptin-deﬁcient mice (ob/ob mice) have been observed to
be obese and sterile. The known hypothalamic mediation of
leptin’s regulation of appetite and reproduction is of interest
as most homeostatic functions are hypothalamically regu-
lated, and bone remodeling may be considered as a
homeostatic function. Analyses of bone from ob/ob mice
showed that they have an increased bone mass.
7 The bone
mass phenotype of ob/ob mice can be rescued by intracer-
ebroventricular (ICV) infusion of leptin, suggesting that
leptin exerts an indirect inﬂuence on bone mass.
7
Mechanism of leptin’s influence on bone mass
Further investigations have explored the pathway of leptin’s
indirect control of bone mass. Clinically, human reﬂex
sympathetic dystrophy is characterized by a rapid onset of
osteoporosis in the affected region with labile vasomotor
activity, trophic skin changes, pain, and swelling, because of
dysregulated sympathetic tone. In some cases, b-blockers
such as propranolol resolve reﬂex sympathetic dystrophy-
associated symptoms and osteopenia.
8 Outside the context of
reﬂex sympathetic dystrophy, people receiving b-blockers
experience 24–32% reductions in the risk of fractures, as
shown in several large studies (Table 1).
9–12 Interestingly,
leptin-deﬁcient mice show a low sympathetic tone. Taken
together, these observations suggest that leptin may exert its
bone control through a neuronal pathway involving the
sympathetic nervous system. This hypothesis has been tested
in a number of in vivo studies.
The ﬁrst key experiment was a parabiosis experiment in
which one of two ob/ob mice with a surgically established
common blood circulation received ICV leptin. Bone analysis
of both animals showed that bone volume was corrected in
the ICV leptin-treated mouse, but not in the related partner,
suggesting that leptin’s control of bone is exerted in a
neuronal rather than an endocrine manner.
13 Moreover, the
treatment of ob/ob mice with isoproterenol, a b-agonist, does
not affect appetite and body weight but does correct bone
volume to normal levels, suggesting that leptin’s effect on
bone may involve b-adrenergic stimulation.
13
Further leptin ICV experiments in ob/ob mice, using
chemical ablation of speciﬁc nuclei in the hypothalamus,
established that leptin separately inhibits appetite through
the arcuate nucleus and bone mass through the ventromedial
hypothalamus (VMH) nucleus. These experiments indicate
that hypothalamic integrity is required in bone regulation.
However, speciﬁc deletion of the hypothalamic leptin
receptor (ObRb) does not inhibit ICV leptin correction,
14
suggesting that leptin ﬁrst acts in a different brain region to
affect a neuromediator that signals secondarily to hypotha-
lamic neurons to modulate bone mass and appetite.
Serotonin as a neuromediator for leptin activity
Serotonin was identiﬁed as a candidate neuromediator for leptin
activity on the basis of the clinical observation that antisero-
toninergic antidepressant drugs such as selective serotonin
reuptake inhibitors increase patients’ appetite and osteoporotic
fracture risk,
15 supporting a role for serotonin in appetite
regulation and control of bone mass.
16 Serotonin is distributed
throughout the body: 95% circulating in blood and 5% in the
brain as a neuromediator. Serotonin does not cross the
blood–brain barrier.
17,18 In the brain, serotonin is formed from
tryptophan by the brain-speciﬁc enzyme tryptophan hydroxylase
2( Tph2), which is highly expressed in the brainstem but not in
the hypothalamus. Tph2-null mutant mice with brain serotonin
deﬁciency have high sympathetic tone and low bone mass
because of high bone resorption and low bone formation.
16
Neuronal connection between leptin and serotonin
Further experiments have explored neuronal connections
between leptin and serotonin. Serotoninergic neurons (expres-
sing Tph2) and leptin receptors are both located in the
brainstem, but until recently it was not clear whether these
serotoninergic neurons project on hypothalamic neurons
(VMH) to regulate bone mass. Yadav et al.
16 examined this
aspect in four experiments. The ﬁrst one used mice expressing a
ﬂuorescent protein in the axons of brainstem Tph2þ neurons
through a Cre recombinase-mediated technology to show that
these axons project to the VMH nucleus. The second
experiment demonstrated histologically by anterograde and
retrograde rhodamine dextran axon tracing that VMH neurons
Table 1|Effect of b-blockers on fracture risk
12
Study Study design Subjects Fracture type
Hazard or
odds ratio (95% CI) Reference
SOF Prospective cohort 8412 (13.1% users) Hip 0.76 (0.58–0.99) Reid et al.
10
GPRD Retrospective case–control 120,819 controls
(17.6% users), 30,601
cases (16% users)
Any 0.77 (0.72–0.83) Schlienger et al.
11
Hip 0.68 (0.52–0.89)
Geelong
Osteoporosis Study
Population-based
case–control
775 controls (14.5% users),
569 cases (10.4% users)
Any 0.69 (0.49–0.96) Pasco et al.
9
Abbreviations: CI, confidence interval; GPRD, General Practice Research Database; SOF, Study of Osteoporotic Fractures.
Kidney International (2011) 79 (Suppl 121), S14–S19 S15
CB Confavreux: Bone energy endocrinology reviewreceive neuronal projections from Tph2 neurons in the
brainstem. The third experiment demonstrated that VMH
neurons express serotonin receptor (Htr2c)a n dt h a tb r a i n s t e m
serotonin neurons express leptin receptor (ObRb). In the fourth
experiment, Htr2c
–/–-deﬁcient mice have a low bone mass
phenotype that is recapitulated by the double knockout strain
(Htr2c
þ/–,T p h 2
þ/–), genetically establishing the action of
serotonin on bone mass in the hypothalamus.
These experiments demonstrate that serotoninergic brain-
stem neurons (Tph2þ) project axons to VMH neurons
expressing serotonin receptor (Htr2c) and that serotonin is
the signal link between the brainstem, where leptin acts on its
receptor (ObRb), and the VMH nucleus in the hypothalamus.
Taken together, these studies show that leptin inhibits bone
formation through a serotonin central relay (brainstem to
hypothalamus) and through hypothalamus-generated sympa-
thetic tone (Figure 1). These key studies showed that fat (energy
metabolism) controls bone mass, but did not address whether
bone exerts a reciprocal inﬂuence on energy metabolism.
THE ROLE OF OSTEOCALCIN IN REGULATION OF ENERGY
METABOLISM BY THE SKELETON
Esp, an osteoblast-specific gene with a metabolic phenotype
Researchers have examined the role of bone in energy meta-
bolism using a three-step research strategy: identiﬁcation of
osteoblast-speciﬁc genes; generation of global and osteoblast-
speciﬁc knockout mutant mice for these genes; and ﬁnally
studies of their energy metabolism phenotype.
The candidate gene Esp encodes osteotesticular protein
tyrosine phosphatase, expressed in embryonic stem cells,
Sertoli cells, and osteoblasts, but not in adipose tissue or
pancreas. Its function was initially unknown in mice and
humans. Esp-deﬁcient mice (Esp
–/–) have early postnatal
lethality, which is not because of a skeletal defect but because
of low blood glucose at birth. Esp
–/– mice have lifelong low
blood glucose and an improved glucose tolerance compared
with wild-type mice.
6 Interestingly, these characteristics
reﬂect hyperinsulinemia, resulting from increased insulin
secretion, increased size and number of pancreatic b-cells,
and improved insulin sensitivity, with reduced visceral fat
and increased adiponectin. Conversely, overexpressing Esp,
speciﬁcally in osteoblasts, impairs glucose handling and
induces a type 2 diabetes-like phenotype with reduced
glucose tolerance because of reduced insulin secretion and
increased peripheral insulin resistance. Thus, osteoblastic
expression of Esp regulates pancreatic insulin production and
adipose insulin sensitivity.
6 These ﬁndings suggested that an
osteoblast-speciﬁc tyrosine phosphatase deletion in mice
improves insulin handling and reduces fat mass. However,
osteotesticular protein tyrosine phosphatase is intracytoplas-
mic and therefore cannot act directly on distant cells to
regulate energy metabolism. Therefore, the next question was
to uncover which speciﬁc hormone is secreted by osteoblasts
and acts on adipocytes and pancreatic b-cells.
Osteocalcin: a bone hormone regulating energy metabolism
Co-cultures of osteoblasts with adipocytes or osteoblasts with
b-cells showed that an osteoblast-secreted factor regulates
insulin and adiponectin expression. This factor, osteocalcin,
shares several properties with other hormones: secretion,
circulation in blood, and regulation. Indeed, osteocalcin is
present in all vertebrates, is secreted by osteoblasts into the
bloodstream and bone matrix, is speciﬁc to osteoblasts, and
exists in carboxylated and uncarboxylated forms, suggesting a
regulatory mechanism. Its function has been unknown
until recently. However, we know that osteocalcin-deﬁcient
mice have a moderate late bone phenotype but an early devel-
opment of obesity, even on a regular diet. The osteocalcin
gene is located in a genomic region that confers risk of
diabetes. Furthermore, the metabolic phenotype of osteocal-
cin-deﬁcient mice is a mirror image of that of Esp-deﬁcient
mice. Osteocalcin-deﬁcient mice have high blood glucose,
hypoinsulinemia, few pancreatic b-cells, and reduced insulin
sensitivity.
6 In addition, treating wild-type mice with
continuously infused uncarboxylated osteocalcin increases
insulin secretion, improves glucose tolerance, and in higher
doses also decreases fat mass.
19
Osteocalcin has been shown to act partly through
adiponectin, which is secreted by adipocytes in response to
osteocalcin, promotes insulin sensitivity, and is reduced in
obese or diabetic persons. Skeletally, adiponectin is correlated
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Figure 1|Interactions between bone and energy metabolism.
Leptin inhibits bone formation through a serotonin central relay
(brainstem to hypothalamus) and through hypothalamus-
generated sympathetic tone. In turn, osteoblasts secrete
osteocalcin, a hormone regulating energy metabolism, through its
stimulation on insulin secretion and sensitivity. Adrb2, b2-adrenergic
receptor; AN, arcuate nucleus; Gla-OCN, carboxylated osteocalcin;
Glu-OCN, uncarboxylated osteocalcin; ObRb, leptin receptor;
OST-PTP, osteotesticular protein tyrosine phosphatase;
SNS, sympathetic nervous system; VMH, ventromedial hypothalamic
nucleus. Adapted from Confavreux.
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5
In humans, epidemiological studies, such as the MrOS
(Osteoporotic Fractures in Men) Sweden study in Swedish
men
20 or the First Nations Bone Health Study in Canadian
women of aboriginal and European heritage,
21 have found
that osteocalcin levels are negatively correlated with fasting
blood glucose in non-diabetic subjects.
In conclusion, osteocalcin is an osteoblast hormone
regulating energy metabolism through its effects on insulin
secretion and sensitivity. Osteoblastic osteocalcin secretion is
partly controlled by the hypothalamus through sympathetic
tone. Sympathetic tone is in turn controlled by leptin
through serotoninergic signaling from the brainstem to the
hypothalamus (Figure 1).
22,23
Osteoblast transcription factors involved in energy
metabolism
Osteoblasts are regulated by the osteoblast transcription
factors, Osx and Runx2, which induce mesenchymal cells to
differentiate into osteoblasts. Activating transcription factor 4
(ATF4) belongs to the cAMP-responsive element-binding
protein transcription factor family, is regulated by sympa-
thetic tone, and controls osteoblast functions such as bone
formation, matrix mineralization, and receptor activator of
nuclear factor kB ligand production. ATF4 also regulates
osteoblast endocrine functions by inducing Esp and Ocn
(the osteoblast endocrine genes). Indeed mice deﬁcient in
ATF4 show enhanced glucose tolerance and insulin sensitiv-
ity.
24 The transcription factor FoxO1, which upregulates the
enzymes of gluconeogenesis, is regulated by insulin.
25
Deleting FoxO1 speciﬁcally in osteoblasts reduces Esp
expression and increases osteocalcin, resulting in a metabolic
phenotype protective against diabetes (Figure 2).
26
Connection between osteocalcin and insulin signaling
through bone remodeling
Until recently, experiments had not yet elucidated how the
tyrosine phosphatase osteotesticular protein tyrosine phos-
phatase inﬂuences synthesis or activity of the hormone
osteocalcin. Moreover, it was not established whether this
process exists in humans as ESP in humans is a pseudogene.
From an endocrine perspective, the fact that osteocalcin
affects insulin raised the hypothesis that insulin should affect
active osteocalcin in a feedback loop. A recent study by
Ferron et al.
27 provided a new key step in deciphering the
interactions between bone and energy metabolism (Figure 3).
Ferron et al. showed that insulin receptor (InsR) is expressed
in osteoblasts and, interestingly, that mice lacking InsR
speciﬁcally in osteoblasts have high blood glucose, low serum
insulin, and altered glucose tolerance. Uncarboxylated
osteocalcin was decreased in these mice. Karsenty’s group
27
established genetically that InsR in osteoblast and osteocalcin
were in the same genetic pathway, as double-mutant hetero-
zygous mice (InsRob
þ/–; Ocn
þ/–) have the same impaired
glucose metabolic phenotype as osteocalcin-deﬁcient mice
(Ocn
–/–). Next, they showed that insulin affects active
osteocalcin in two ways: (1) insulin receptor is a substrate
of the tyrosine phosphatase osteotesticular protein tyrosine
phosphatase in mice and of protein tyrosine phosphatase 1B
in humans; and (2) insulin receptor-deﬁcient mice (InsR ob
–/–)
have decreased bone resorption because of overexpression of
osteoprotegerin, which blocks osteoclastogenesis and bone
resorption. During bone resorption, the osteoclast vacuolar
proton pump acidiﬁes the sealed extracellular compartment,
which decarboxylates osteocalcin into active uncarboxylated
osteocalcin released into the bloodstream. This was estab-
lished using osteoclast proton pump Tcirg1-deﬁcient mice
(Oc/Oc), which have an impaired glucose phenotype. In
Insulin
InsR
FoxO1 ATF4
SNS
Adrβ2
Osteoblast
OST-PTP OPG
Osteoprotegerin Osteocalcin Esp
OCN
Figure 2|Osteoblast signaling pathways involved in energy
metabolism regulation. Effects of insulin and sympathetic
nervous system (SNS) on osteocalcin (OCN), osteotesticular
protein tyrosine phosphatase (OST-PTP), and osteoprotegerin
(OPG). Adrb2, b2-adrenergic receptor; ATF4, activating
transcription factor 4; InsR, insulin receptor. Adapted from
Confavreux.
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Figure 3|Insulin and bone resorption affect circulating
uncarboxylated osteocalcin (Glu-OCN). Insulin binds its
receptor (InsR), which reduces osteoprotegerin (OPG) expression,
thus enhancing osteoclast formation and activity. During bone
resorption, acidification of the extracellular compartment
decarboxylates inactive osteocalcin (Gla-OCN) to Glu-OCN.
Glu-OCN is then released into the blood stream to affect target
tissues. OST-PTP, osteotesticular protein tyrosine phosphatase.
Adapted from Cell,
27 with permission from Elsevier.
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nuclear factor kB ligand to obtain high bone resorption have
an improved glucose tolerance.
27
In summary, insulin signaling in osteoblasts improves
glucose handling directly by increasing secretion of active
uncarboxylated osteocalcin and indirectly by enhancing
bone resorption, which releases uncarboxylated osteocalcin
into the bloodstream; uncarboxylated osteocalcin then affects
energy metabolism. Together, these ﬁndings raise many
metabolic questions regarding the level of bone remodeling
in diseases, and the effect of widely used antiresorptive
therapies.
INSIGHTS INTO BONE, KIDNEY, AND ENERGY METABOLISM
The role of leptin in bone, kidney, and energy metabolism is
still under investigation. Recently, it was shown that leptin
administered to leptin-deﬁcient mice stimulated ﬁbroblast
growth factor-23 synthesis and inhibited renal 1a-hydrox-
ylase. Thus, leptin reduces serum calcium, serum phosphate,
and active 1,25(OH)2D3 formation. Leptin replacement in
ob/ob mice also signiﬁcantly reduced renal NaPi-2a, NaPi-2c,
and 1a-hydroxylase expression. These effects required the
leptin receptor, as mice lacking leptin receptor (db/db) did
not increase Fgf-23 or 1a-hydroxylase expression in response
to leptin.
28 Moreover, leptin appears to promote osteoblastic
differentiation of vascular smooth muscle cells and thus may
contribute to vascular calciﬁcation stimulated by hyperphos-
phatemia in CKD.
29,30
Some other bone–energy–kidney connections have also
been suggested. In patients with CKD, serum adiponectin is
inversely correlated with integral and cortical volumetric
bone mineral density and cortical thickness, and serum
osteocalcin is positively correlated with serum adiponectin.
31
A randomized controlled trial is currently examining the
effect of vitamin D supplementation on insulin resistance,
serum adiponectin, serum osteocalcin, and multiple inﬂam-
matory markers in patients with CKD.
32
In conclusion, the nascent ﬁeld of bone–energy metabo-
lism, a paradigm of integrative physiology, has only been
made possible by the onset of mouse genetics.
23 Future
research is needed to decipher the mechanisms of the
bone–energy endocrine axis and its relationship to other body
systems. The transfer of discoveries made in mouse models
into research in humans is in progress.
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